

DAFTAR PUSTAKA

1. WHO Coronavirus (COVID-19) [Internet]. Covid19.who.int. 2021 [cited 19 August 2021]. Available from: <https://covid19.who.int>
2. Kementerian Kesehatan Republik Indonesia [Internet]. Kemkes.go.id. 2021 [cited 19 August 2021]. Available from: <https://www.kemkes.go.id>
3. Blanco-Melo D., B.E. Nilsson-Payant, W.C. Liu, et al., Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19, *Cell* 181 (5) (2020)1036–1045
4. Hadjadj J., Yatim N., Barnabei L, et al., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, *Science* 369 (6504) (2020) 718–724,
5. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. *Biomedicine & Pharmacotherapy*. 2020;131:110698
6. Li H, He X, Zhang L, Li C, Li S, Li Q. Therapeutic Agents Rounding Up the Immunopathology of COVID-19. *Therapeutics and Clinical Risk Management*. 2021;Volume 17:657-668.
7. Rizk J, Kalantar-Zadeh K, Mehra M, Lavie C, Rizk Y, Forthal D. Pharmaco-Immunomodulatory Therapy in COVID-19. *Drugs*. 2020;80(13):1267-1292
8. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. *Journal of Autoimmunity*. 2020;111:102452.
9. Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. *International Journal of Molecular Sciences*. 2020;21(9):3377.
10. Kementrian Kesehatan Republik Indonesia. "Protokol Tatalaksana COVID-19." Jakarta: PDPI, PERKI, PAPDI, PERDATIN, IDAI. 2021:50.
11. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. *ChinaXiv*. 2020;202003(00026):v1
12. Mazzone A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *Journal of Clinical Investigation*. 2020;130(9):4694-4703.
13. Alattar R., Ibrahim T.B.H., Shaar S.H., et al., Tocilizumab for the treatment of severe coronavirus disease 2019 [published online ahead of print, 2020 May 5], *J Med Virol*. (2020)
14. Borku Uysal B., Ikitimur H., Yavuzer S., et al., Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients [published online ahead of print, 2020 Jun 2], *J Med Virol*. (2020), <https://doi.org/10.1002/jmv.26111>
15. Wu Y, Chen C, Chan Y. The outbreak of COVID-19: An overview. *Journal of the Chinese Medical Association*. 2020;83(3):217-220.

16. Calabrese L. Cytokine storm and the prospects for immunotherapy with COVID-19. *Cleveland Clinic Journal of Medicine*. 2020;87(7):389-393.
17. Rumende C, Susanto E, Sitorus T. The Management of Cytokine Storm in COVID-19. *Acta Med Indones - Indones J Intern Med*. 2020;52(3):306-313.
18. Jacques F, Apedaile E. Immunopathogenesis of COVID-19: Summary and Possible Interventions. *Frontiers in Immunology*. 2020;11
19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. (2020) 395:1054–62.
20. Fajgenbaum D, June C. Cytokine Storm. *New England Journal of Medicine*. 2020;383(23):2255-2273
21. Kaur S, Bansal R, Kollimuttathuillam S, Gowda A, Singh B, Mehta D et al. The looming storm: Blood and cytokines in COVID-19. *Blood Reviews*. 2021;46:100743.
22. Bordallo B, Bellas M, Cortez A, Vieira M, Pinheiro M. Severe COVID-19: what have we learned with the immunopathogenesis?. *Advances in Rheumatology*. 2020;60(1).
23. Kronbichler A, Effenberger M, Eisenhut M, Lee K, Shin J. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. *Autoimmunity Reviews*. 2020;19(7):102570.
24. Zhang Y, Chen Y, Meng Z. Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. *Frontiers in Immunology*. 2020;11.
25. Kempuraj D, Selvakumar G, Ahmed M, Raikwar S, Thangavel R, Khan A et al. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. *The Neuroscientist*. 2020;26(5-6):402-414.
26. Henderson L, Canna S, Schulert G, Volpi S, Lee P, Kernan K et al. On the Alert for Cytokine Storm: Immunopathology in COVID -19. *Arthritis & Rheumatology*. 2020;72(7):1059-1063.
27. Keam S, Megawati D, Patel S, Tiwari R, Dhama K, Harapan H. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. *Reviews in Medical Virology*. 2020;30(5).
28. Azkur A, Akdis M, Azkur D, Sokolowska M, Veen W, Brügger M et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy*. 2020;75(7):1564-1581.
29. Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med*. Epub ahead of print 10 April 2020.

30. Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. *Int J Infect Dis*. Epub ahead of print 22 April 2020.
31. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine & Growth Factor Reviews*. 2020;53:25-32.
32. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *Journal of Autoimmunity*. 2020;111:102452.+1
33. Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. *Therapeutic Advances in Respiratory Disease*. 2020;14:175346662093350.
34. Arnaldez F, O'Day S, Drake C, Fox B, Fu B, Urba W et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. 2021.
35. Copaescu A, Smibert O, Gibson A, Phillips E, Trubiano J. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *Journal of Allergy and Clinical Immunology*. 2020;146(3):518-534.e1.
36. Notz Q, Schmalzing M, Wedekink F, Schlesinger T, Gernert M, Herrmann J et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. *Frontiers in Immunology*. 2020;11.
37. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. *Autoimmunity Reviews*. 2020;19(6):102537.
38. Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. *Life Sciences*. 2020;257:118097.
39. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., Zhong, N. S. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England journal of medicine*, 382(18), 1708-1720.
40. Luo, Y., Xie, Y., Zhang, W., Lin, Q., Tang, G., Wu, S., Sun, Z. (2019). Combination of lymphocyte number and function in evaluating host immunity. *Aging (Albany NY)*, 11(24), 12685-12707.
41. Ayres, J. S. (2020). Surviving COVID-19: A disease tolerance perspective. *Science advances*, 6(18)

42. Fehr A.R., Channappanavar R., and Perlman S.: Middle East respiratory syndrome: emergence of a pathogenic human coronavirus. *Annu Rev Med* 2017; 68: pp. 387-399
43. Braun G.S., Nagayama Y., Maruta Y., et al: IL-6 trans-signaling drives murine crescentic GN. *J Am Soc Nephrol* 2016; 27: pp. 132-142
44. Kang S., Tanaka T., Narazaki M., et al: Targeting interleukin-6 signaling in clinic. *Immunity* 2019; 50: pp. 1007-1023
45. ones S.A., and Jenkins B.J.: Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. *Nat Rev Immunol* 2018; 18: pp. 773-789
46. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. *International Journal of Antimicrobial Agents*. 2020;55(6):105982.
47. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. *J Med Virol*. 2020.
48. Saha Abinit et al. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. *Archives of Medical Research*, 2020-08-01, Volume 51, Issue 6, Pages 595-597,
49. Langer-Gould A., et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. *International Journal of Infectious Diseases*, 2020-10-01, Volume 99, Pages 291-297
50. Kaur S, Bansal R, Kollimuttathuillam S, Gowda A, Singh B, Mehta D et al. The looming storm: Blood and cytokines in COVID-19. *Blood Reviews*. 2021;46:100743.
51. Nugroho C, Suryantoro S, Yuliasih Y, Rosyid A, Asmarawati T, Andrianto L et al. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis. *F1000Research*. 2021;10:73.
52. World Health Organization. Therapeutics and Covid 19 Living Guideline. 2021;28
53. Iannaccone G, Scacciavillani R, Del Buono M, Camilli M, Ronco C, Lavie C et al. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. *Cardiorenal Medicine*. 2020;10(5):277-287.
54. I Made Prema Putra. Pendekatan Sepsis dengan Skor SOFA. *CDK-267/* 2018. vol. 45 no. 8 th.
55. Rajendram, P; et al. Tocilizumab in Coronavirus Disease 2019 - Related Critical Illness: A Propensity Matched Analysis, *Critical Care Explorations*: January 2021 - Volume 3 - Issue 1 - p e0327.
56. Yang Z, Hu Q, Huang F, Xiong S, Sun Y. The prognostic value of the SOFA score in patients with COVID-19: A retrospective, observational study. *Medicine (Baltimore)*. 2021;100(32):e26900.
57. Gruyters I, De Ridder T, Bruckers L, et al. Predictive value of serial evaluation of the Sequential Organ Failure Assessment (SOFA) score for intensive care unit

- mortality in critically ill patients with COVID-19: a retrospective cohort study. *Anesthesiology Intensive Therapy*. 2022;54(1):3-11.
58. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent J. Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients. *JAMA*. 2001;286(14):1754–1758.
 59. Guaraldi G, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol*. 2020 Aug;2(8):e474-e484.
 60. Khurshid S, et al. Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center. *Cureus*. 2021 Nov 30;13(11):e20031.
 61. Austin R. et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab, *Journal of Autoimmunity*, Volume 114, 2020
 62. Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. *J Med Virol*. 2020
 63. Hariyanto IT, Kurniawan A. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. *J Med Virol*. 2021;93(3)
 64. Issa N, Dumery M, Guisset O, Mourissoux G, Bonnet F, Camou F. Feasibility of tocilizumab in ICU patients with COVID-19. *J Med Virol*. 2020.
 65. De Rossi N, Scarpazza C, Filippini C, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. *Eclin Med*. 2020